

## *Safety of Hydroxychloroquine in COVID-19*

### **1 Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19**

2  
3 Sarah M Lofgren,<sup>1</sup> Melanie R Nicol,<sup>1</sup> Ananta S Bangdiwala,<sup>1</sup> Katelyn A Pastick,<sup>1</sup> Elizabeth C  
4 Okafor,<sup>1</sup> Caleb P Skipper,<sup>1</sup> Matthew F Pullen,<sup>1</sup> Nicole W Engen,<sup>1</sup> Mahsa Abassi,<sup>1</sup> Darlisha A  
5 Williams,<sup>1</sup> Alanna A Nascene,<sup>1</sup> Margaret L Axelrod,<sup>2</sup> Sylvain A Lothier,<sup>3</sup> Lauren J MacKenzie,<sup>3</sup>  
6 Glen Drobot,<sup>3</sup> Nicole Marten,<sup>4</sup> Matthew P Cheng,<sup>6,7</sup> Ryan Zarychanski,<sup>3,4</sup> Ilan S Schwartz,<sup>5</sup>  
7 Michael Silverman,<sup>8</sup> Zain Chagla,<sup>9</sup> Lauren E Kelley,<sup>4</sup> Emily G McDonald,<sup>6,7</sup> Todd C Lee,<sup>6,7</sup>  
8 Katherine H Hullsiek,<sup>1</sup> David R. Boulware,<sup>1</sup> Radha Rajasingham.<sup>1</sup>

9  
10  
11  
12 1 University of Minnesota, Minneapolis, Minnesota  
13 2 Vanderbilt University Medical Center, Nashville, Tennessee  
14 3 Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba  
15 4 George & Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba  
16 5 Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton,  
17 Alberta  
18 6 Research Institute of the McGill University Health Centre, Montreal, Quebec  
19 7 Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal,  
20 Quebec  
21 8 Lawson Research Institute, St. Joseph's Healthcare Center, London, Ontario  
22 9 McMaster University, Hamilton, Ontario

23  
24  
25  
26 Keywords: Hydroxychloroquine, Covid-19, Safety, SARS-Cov2, Side-effects

27  
28 Word Count: Total: 2802; Abstract 243

29  
30  
31 Corresponding author: Dr. Sarah Lofgren, 689 23rd Avenue S.E., Minneapolis, MN 55455;  
32 Phone 612-624-4171; Lofg0020@umn.edu

33  
34 Dr. Rajasingham is the Alternative Corresponding Author: radha@umn.edu

35  
36 Clinicaltrials.gov Identifier:

37 NCT04308668 for post-exposure prophylaxis and early treatment trials.

38 NCT04328467 for pre-exposure prophylaxis trial.

### **40 41 Short Summary**

*Safety of Hydroxychloroquine in COVID-19*

42 Data from three randomized clinical trials using hydroxychloroquine for the prevention and  
43 treatment of COVID-19 did not suggest significant safety concerns. Gastrointestinal side effects  
44 were common but arrhythmias were rare. There were no sudden deaths in any trial.  
45

## *Safety of Hydroxychloroquine in COVID-19*

### 46 **Abstract**

47 **Introduction:** Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in  
48 combination with azithromycin, has raised safety concerns. Here, we report safety data from  
49 three outpatient randomized clinical trials.

50 **Methods:** We conducted three randomized, double-blind, placebo-controlled trials investigating  
51 hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early  
52 treatment for COVID-19. We excluded individuals with contraindications to hydroxychloroquine.  
53 We collected side effects and serious adverse events. We report descriptive analyses of our  
54 findings.

55 **Results:** We enrolled 2,795 participants. The median age of research participants was 40 (IQR  
56 34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2,324  
57 (84%) participants reported side effect data, and 638 (27%) reported at least one medication  
58 side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once  
59 weekly hydroxychloroquine compared to 19% with placebo. The most common side effects  
60 were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs.  
61 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice  
62 weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial  
63 arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths  
64 occurred.

65 **Conclusion:** Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side  
66 effects were common but mild with the use of hydroxychloroquine, while serious side effects  
67 were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials can  
68 safely investigate whether hydroxychloroquine is efficacious for COVID-19.

69

## *Safety of Hydroxychloroquine in COVID-19*

### 70 **Introduction:**

71 Hydroxychloroquine has *in vitro* antiviral activity against *Severe Acute Respiratory*  
72 *Syndrome-related coronavirus 2* (SARS-CoV-2).[1, 2] While *in vitro* data suggest that both  
73 chloroquine and hydroxychloroquine have activity against SARS-CoV-2 replication, the latter is  
74 generally considered less toxic and better tolerated. However, clinical data to date demonstrate  
75 no conclusive efficacy of hydroxychloroquine for the treatment or prevention of COVID-19.[3-5]  
76 Both chloroquine and hydroxychloroquine impede SARS-CoV-2 replication.[2] Several  
77 randomized placebo-controlled clinical trials are underway to evaluate hydroxychloroquine's  
78 safety and efficacy in the prevention and treatment of COVID-19 in both inpatient and outpatient  
79 populations.[6]

80 In late March 2020, hydroxychloroquine had substantial positive coverage in the media.  
81 However, the tide rapidly turned due to concerted efforts to inform physicians and patients about  
82 the potential risks of taking the drug outside of clinical trial settings.[7] Several inpatient  
83 treatment studies then went on to show increased cardiac side effects with hydroxychloroquine  
84 and azithromycin.[8, 9] On April 24th, 2020, the U.S Food and Drug Administration (FDA) issued  
85 a caution against chloroquine and hydroxychloroquine in the treatment of COVID-19 outside of  
86 hospital settings or clinical trials.[10] The FDA stated, "Hydroxychloroquine and chloroquine can  
87 cause abnormal heart rhythms such as QT interval prolongation and...ventricular tachycardia."  
88 The FDA noted that QT prolongation was more common among persons receiving azithromycin  
89 and those with prior heart problems or kidney disease.

90 Hydroxychloroquine nonetheless has a 65-year track record of safety when prescribed at  
91 recommended doses in populations with normal liver and kidney function, and without pre-  
92 existing cardiac arrhythmias.[11] In the medical specialties of tropical medicine and  
93 rheumatology, chloroquine and hydroxychloroquine have routinely been prescribed without  
94 baseline laboratory testing or EKG monitoring. Whether these tests should be performed in the  
95 setting of hydroxychloroquine for COVID-19 is controversial. As it stands, a number of ongoing

## *Safety of Hydroxychloroquine in COVID-19*

96 clinical trials have been paused or halted by regulatory authorities over concerns related to the  
97 potential for QT prolongation. Importantly, these safety concerns have risen from reports of  
98 hydroxychloroquine use in hospitalized patients, who are more likely to have severe infections,  
99 significant comorbidities and be on multiple concurrent medications.[12]

100       There are some features of the SARS-CoV-2 virus which may predispose individuals  
101 with COVID-19 to be more likely to have complications from drugs that prolong the QT than  
102 healthy individuals. SARS-CoV-2 itself can enter cardiomyocytes and may cause direct cardiac  
103 injury.[13-15] Multiple reports of increased arrhythmias in individuals with COVID-19 without  
104 other cause, suggest SARS-CoV-2 itself may cause arrhythmias.[15] Alternatively, elevated  
105 cytokines directly or in concert with cardiomyocyte damage, may predispose to arrhythmias.[16]  
106 Additionally, COVID-19 is associated with significant electrolyte imbalances, including sodium,  
107 potassium, and calcium as well as renal failure, each of which also predispose individuals to  
108 arrhythmias.[15, 17] Therefore testing the safety of hydroxychloroquine in individuals with  
109 COVID-19 specifically is valuable.

110       The safety of hydroxychloroquine use for COVID-19 in outpatients has not been  
111 established, but is believed to be less risky in outpatients than inpatients.[18] To address  
112 current knowledge gaps regarding the safety and tolerability of hydroxychloroquine in the  
113 outpatient prevention and treatment of COVID-19, and to inform its future usage in the setting of  
114 clinical trials, we present the safety data from three randomized placebo-controlled clinical trials  
115 of hydroxychloroquine in North America.

116

### 117 **Methods:**

#### 118 *Study Design:*

119       We conducted three randomized, double-blind, placebo-controlled trials investigating  
120 hydroxychloroquine as prophylaxis and treatment for COVID-19 disease. The first two trials

## *Safety of Hydroxychloroquine in COVID-19*

121 evaluated: 1) post-exposure prophylaxis (PEP); 2) preemptive early treatment (PET),  
122 (Clinicaltrials.gov Identifier: NCT04308668).[3, 19] Trial enrollment began on March 17, 2020,  
123 concluded on May 6, and follow up was completed on May 20, 2020. The third trial assessed  
124 pre-exposure prophylaxis (PREP) for COVID-19 (ClinicalTrials.gov Identifier: NCT04328467).  
125 Enrollment for this third trial began April 6 and ended May 26, 2020, with follow-up concluding  
126 on July 13, 2020.  
127 In each of these trials, participants were randomized to receive placebo or hydroxychloroquine.  
128 The PEP trial required participants to have a known exposure to a lab-confirmed COVID-19  
129 case within four days either as a household contact or as a healthcare worker or first responder.  
130 The PET trial enrolled persons with COVID-19 symptoms of four or fewer days duration and  
131 either lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of  
132 symptom onset. The PREP required persons to be high-risk healthcare workers or first  
133 responders with ongoing occupational exposure to COVID-19.

134 Hydroxychloroquine dosing for both the PEP and PET trials was 800mg load dosing,  
135 followed by 600mg in 6-8 hours, and then 600mg daily for five days in total. Participants were  
136 instructed to split their follow-up dosing in the event of gastrointestinal upset. In designing the  
137 trials, investigators chose doses within the existing FDA-approved dosing range that were  
138 modeled to achieve therapeutic concentrations from day 1 through 10.[20] Hydroxychloroquine  
139 dosing for PREP was dosed at 400 mg orally once, followed by 400mg 6 to 8 hours later,  
140 thereafter 400mg weekly or twice weekly for the duration of follow-up, up to 12 weeks. The  
141 placebo was dosed similarly.

142

### *Study Participants:*

144 Participants were enrolled in the three trials via internet-based surveys throughout the  
145 United States and selected Canadian provinces. Full details are online (Clinicaltrials.gov  
146 Identifier: NCT04308668, NCT04328467).[3] Participants were excluded if they were <18 years

## *Safety of Hydroxychloroquine in COVID-19*

147 old, had an allergy to hydroxychloroquine, retinal eye disease, known glucose-6 phosphate  
148 dehydrogenase (G6PD) deficiency, known chronic kidney disease, stage 4 or 5 or receiving  
149 dialysis, known porphyria, weight <40 kg, known QT prolongation, or receiving chemotherapy.  
150 Current use of hydroxychloroquine, azithromycin, or cardiac arrhythmia medicines (flecainide,  
151 amiodarone, digoxin, procainamide, propafenone, or sotalol) were also exclusion criteria. On  
152 April 20, 2020, the FDA required additional exclusions of structural or ischemic heart disease  
153 and personal or family history of cardiac QT prolongation, and medications that prolong the QTc  
154 interval.

155 Health Canada mandated additional exclusions for Canadian participants. Women who  
156 were pregnant or breastfeeding were excluded, as were patients with: severe diarrhea or  
157 vomiting; known cirrhosis with a history of encephalopathy or ascites; known prolonged cardiac  
158 QTc interval, history of ventricular arrhythmia or history of sudden cardiac death; patients taking  
159 additional medicines that had a high risk of prolonging the electrocardiogram QTc interval in  
160 conjunction with hydroxychloroquine. The Institutional Review Board (IRB) in Ontario also  
161 mandated that a physician perform a complete review of medications for participants above age  
162 65, to exclude those with important drug-drug interactions.

163 Participants in the PEP and PET trials completed follow-up email surveys on Days 1, 3,  
164 5, 10, and 14, whereas participants in the PREP trial completed weekly follow-up surveys.  
165 Surveys obtained self-report of study drug adherence, side effects, new COVID-19 symptoms,  
166 new COVID-19 testing, and hospitalization. For participants who stopped their study drug due to  
167 side effects or other reasons, we encouraged them to continue observational follow-up and  
168 completion of self-report surveys.

169

170

171 *Statistical Analysis:*

## *Safety of Hydroxychloroquine in COVID-19*

172           The analysis presented is primarily descriptive, summarizing the frequency of reported  
173 medication side effects and medication-related serious adverse events, such as hospitalization,  
174 life-threatening events, or deaths. With follow-up ongoing for the PREP study at the time of  
175 publication, data through June 25, 2020, are included in this analysis.

176

177

178 *Approvals:*

179           IRB approval occurred at McGill University, Clinical Trials Ontario, University of  
180 Manitoba, and University of Alberta, and the University of Minnesota.

181

182

183

184 **Results:**

185           A total of 2795 individuals were enrolled into the three trials. The combined median age  
186 was 40 years (interquartile range [IQR] 34-49) and 51% were women. The median weight was  
187 79 kg (IQR 66-91). The majority of participants (74%) were healthcare workers and first  
188 responders. Approximately 66% of the participants were taking no chronic medications, and  
189 59% had no chronic medical conditions. Demographic data are displayed in **Table 1**.

190

191 *Post-exposure prophylaxis and early treatment trials*

192           Of 1312 (n=821 PEP; n=491 PET) participants randomized, 87% (n=1139) started study  
193 drug and completed follow-up surveys. Of 130 participants who started drug but did not  
194 complete follow up, vital status was obtained for 32% (42/130), and all were alive. For the  
195 remainder, we performed an internet search for death records and found none.

## *Safety of Hydroxychloroquine in COVID-19*

196           Of 1139 who started study drug and reported side effect data, 29% reported one or  
197 more side effects, with more side effects reported among those on hydroxychloroquine (40%)  
198 versus placebo (18%) (**Table 2**). The most common side effects reported were upset stomach  
199 or nausea (25% on hydroxychloroquine versus 9% on placebo), followed by vomiting, diarrhea,  
200 or other GI symptoms (23% on hydroxychloroquine versus 6% on placebo), and neurologic  
201 reactions, such as lightheadedness or dizziness (7% on hydroxychloroquine versus 5% on  
202 placebo). Self-reported allergic reactions, occurred in 7 participants (6 on hydroxychloroquine  
203 and 1 on placebo). There were no reported episodes of arrhythmias or sudden cardiac death.

204           Only 46 participants (4%) from the PEP and PET trials reported that they stopped the 5-  
205 day treatment course due to side effects. The distribution of side effects was similar among both  
206 trials. No serious adverse events, resulting in hospitalization, attributable to medication side  
207 effects were reported.

208           Since gastrointestinal issues are known to occur in COVID-19, we compared side effects  
209 between the placebo groups in the PEP group versus those who had COVID-19 in the PET  
210 group. We did not identify a statistical difference in the incidence of nausea / upset stomach  
211 reports in those with COVID-19 versus those exposed (11% vs. 8%,  $p=0.12$ ). Similarly, the  
212 incidence of diarrhea, abdominal pain, vomiting, or other gastrointestinal issues did not differ  
213 between those with COVID-19 versus those exposed (7% vs. 4%,  $p=0.14$ ). The risk of having  
214 any side effects did not differ by sex, age group, weight, or if one was a healthcare worker or not  
215 (**Table 3**).

216

### *Pre-exposure prophylaxis trial*

218           Interim data June 25, 2020, demonstrated that of 1483 randomized, 1402 had follow up  
219 data. Overall, 409 (29%) individuals experienced at least one side effect during the study (**Table**  
220 **4**). Side effects were higher for those receiving hydroxychloroquine: 36% of those on twice-  
221 weekly dosing, 31% on weekly dosing, and 21% on placebo reported at least one side effect.

### *Safety of Hydroxychloroquine in COVID-19*

222 Similar to the other trials, the most common side effects reported were upset stomach or  
223 nausea (18% on hydroxychloroquine twice weekly, 16% on hydroxychloroquine weekly, and  
224 12% on placebo), followed by vomiting, diarrhea, or other GI symptoms (16% on  
225 hydroxychloroquine twice weekly, 12% on hydroxychloroquine weekly, and 6% on placebo).  
226 Two participants experienced atrial arrhythmias. One participant on placebo was hospitalized  
227 twice with atrial fibrillation. Another participant on hydroxychloroquine twice weekly was  
228 hospitalized after a syncopal event and was found to have a supraventricular tachycardia. No  
229 ventricular arrhythmias were reported.

230 In total, across the three cohorts, 25 individuals have been hospitalized through June 25,  
231 2020 (1% incidence). The PEP trial had two hospitalizations, one in each arm and no deaths.  
232 The PET trial had 14 hospitalizations and two deaths. With hydroxychloroquine, 4  
233 hospitalizations and 1 non-hospitalized death occurred. With placebo, 10 hospitalizations  
234 occurred with one hospitalized death. Two hospitalizations were for non-COVID-19, non-study  
235 medication related reasons, while the remaining 12 hospitalizations were due to COVID-19.  
236 Nine individuals were hospitalized from the PREP study, one for COVID-19, two for arrhythmias  
237 (one on hydroxychloroquine twice a day and one on placebo), and the other seven  
238 hospitalizations were for non-study related reasons. No sudden unexplained deaths have been  
239 reported in any of the three trials. Full details are in **Supplemental Table 1**.

240

#### **Discussion:**

242 Among 2464 participants reporting on side effects from 3 randomized clinical trials  
243 investigating the efficacy of hydroxychloroquine in outpatient COVID-19 prevention and  
244 treatment, 27% reported at least one medication-related side effect. We captured one episode  
245 of supraventricular tachyarrhythmia with syncope in an individual on hydroxychloroquine and  
246 two episodes of atrial fibrillation in one individual on placebo. Whether hydroxychloroquine was

### *Safety of Hydroxychloroquine in COVID-19*

247 responsible or contributed to the development of the supraventricular tachycardia is unclear.  
248 Hydroxychloroquine prolongs the QT interval and therefore is associated with an increased risk  
249 of ventricular arrhythmias, not atrial arrhythmias. Regardless, atrial arrhythmias were rare in  
250 both arms, and there were no episodes of ventricular arrhythmia or sudden death in  
251 approximately 50,000 patient-days of cumulative exposure.

252 As expected, the most common side effects were nausea and gastrointestinal upset. In  
253 addition to hydroxychloroquine, COVID-19 is also known to cause gastrointestinal upset.  
254 However, when we compared the rate of gastrointestinal upset among those receiving placebo  
255 in the post-exposure prophylaxis cohort versus those in the symptomatic cohort, reported  
256 gastrointestinal side effects were not significantly more frequent. Most participants regarded  
257 gastrointestinal upset as tolerable and completed the course of medication.

258 Medications causing QT prolongation are feared due to the risk of inducing ventricular  
259 arrhythmias, yet reports of arrhythmias due to hydroxychloroquine use are most often reported  
260 in the setting of co-ingestion, chronic use, or overdose.[21-23] The FDA does not recommend  
261 hydroxychloroquine be used with other agents that prolong the QTc,[11] such as  
262 azithromycin.[24] In 2017, the World Health Organization (WHO) reported that there has never  
263 been a reported sudden cardiac death attributable to chloroquine when prescribed at malaria  
264 treatment doses.[25] Despite the long history of chloroquine/hydroxychloroquine for malaria  
265 treatment and rheumatological diseases such as lupus, there have been increasing concerns  
266 around side effects in patients with COVID-19, especially related to arrhythmias.[26, 27] The  
267 FDA has now changed their emergency use authorization recommendation for  
268 hydroxychloroquine in COVID-19 treatment and prevention for this reason, among many others.  
269 [10]

270 For context, a perspective on dosing is needed to understand potential risks with  
271 chloroquine/hydroxychloroquine. Decades of safety data are available for the standard doses of  
272 chloroquine used for malaria prophylaxis (500 mg [300 mg chloroquine base] weekly) and

### *Safety of Hydroxychloroquine in COVID-19*

273 malaria treatment (2.5 g [1.5g chloroquine base] total over three days). Cardiac conduction  
274 alterations were mostly seen when using much higher doses in hospitalized patients with  
275 COVID-19 (12 g chloroquine base over 10 days).[9] The cumulative dose of  
276 hydroxychloroquine-base used in our PEP and PET trials is 3.8 g (2.9 g base) total over 5 days.  
277 This is in line with established safe dosing strategies and below the doses shown to cause  
278 harmful effects.[28, 29] The Outcomes Related to COVID-19 Treated with Hydroxychloroquine  
279 among In-patients with Symptomatic Disease (ORCID) trial used 400 mg twice on day one  
280 followed by 200 mg twice daily for five days total (ClinicalTrials.gov Identifier: NCT04332991).  
281 They enrolled 479 individuals and also found no significant safety concerns at that dose.[30]  
282 Similarly, the RECOVERY trial used 2.4 g (1.86 g base) in four divided doses over 24 hours,  
283 followed by 800 mg (620 mg base) for an additional 9 days or until discharge and they reported  
284 no significant safety concerns in 11,000 hospitalized patients with COVID-19 randomized to  
285 hydroxychloroquine or placebo.[31]

286 Our trials additionally excluded participants taking azithromycin and other QT-prolonging  
287 drugs to enhance safety further. Other risk factors for QT prolongation, such as hypokalemia or  
288 hypomagnesemia, are uncommon in outpatients.[32, 33] Mercurio, et al. found QTc prolongation  
289 at 2.4 g courses of hydroxychloroquine over five days, but only clinically concerning side effects  
290 when combined with azithromycin and side effects were more common among those already on  
291 loop diuretics.[8] Our data showed one potential cardiac complication (atrial arrhythmia) in one  
292 individual on hydroxychloroquine and one on placebo. Our potential rate of atrial arrhythmias  
293 due to hydroxychloroquine is less than one in 1000. Many commonly used drugs, including  
294 antibacterial, antifungal, and other antimalarial drugs, are known to prolong the QT, thereby  
295 having a rare occurrence of arrhythmias.[34] The risk of QT prolongation has not precluded the  
296 use of drugs such as ciprofloxacin or fluconazole in most patients, but has required clinicians  
297 exercise caution.

## *Safety of Hydroxychloroquine in COVID-19*

298           Despite our rational design of these clinical trials, several limitations still exist. A  
299           significant limitation of our studies is related to their pragmatic nature, which relied on accurate  
300           self-reporting. We did not prospectively record or evaluate for laboratory abnormalities or QTc  
301           changes. While we have outcome data on 93% of participants who have completed the studies,  
302           it is possible, given the passive nature of self-reported follow-up, that those lost-to-follow-up  
303           may have had an adverse event that was not reported to our study team or their designated  
304           emergency contacts. Additionally, our cohorts are relatively young, with a median age of 40.  
305           They had few comorbidities and were on few medications. They were also predominantly  
306           healthcare workers, comprising a population of individuals with high health literacy. All these  
307           factors make our outpatient research participants healthier than most hospitalized patients in  
308           North America. Finally, our study exclusively included outpatients. Patients admitted to hospital  
309           are generally older and have more comorbidities. They also are more likely to have cardiac  
310           complications of COVID-19 and thus may be more susceptible to develop adverse effects from  
311           hydroxychloroquine.

312

### **313 Conclusion**

314           While efforts towards the development of a vaccine continue, agents that can prevent  
315           and treat COVID-19 are important. There is still equipoise concerning the potential efficacy of  
316           hydroxychloroquine as an effective agent against COVID-19; thus, timely completion of  
317           randomized placebo-controlled clinical trials is essential. Thus, large scale clinical trials to  
318           carefully evaluate the limited potential therapeutics that have been identified and perhaps even  
319           to replicate results of completed trials are imperative to our public health response. Ongoing  
320           clinical trials can safely continue with research participants and regulatory bodies reassured as  
321           to the general safety of hydroxychloroquine when using appropriate exclusion criteria.

322

## *Safety of Hydroxychloroquine in COVID-19*

323 **Conflicts of Interest:** Authors are actively involved in clinical trials to prevent or treat COVID-  
324 19. No author has a financial interest in remote EKG monitoring products or services.

325

326

### 327 **Acknowledgments**

328 This work was supported by Jan and David Baszucki, Steve Kirsch, the Alliance of  
329 Minnesota Chinese Organizations, the Minnesota Chinese Chamber of Commerce, and the  
330 University of Minnesota. Personnel was supported through the Doris Duke Charitable  
331 Foundation through a grant supporting the Doris Duke International Clinical Research Fellows  
332 Program at the University of Minnesota. Katelyn Pastick and Elizabeth Okafor are Doris Duke  
333 International Clinical Research Fellows. Sarah Lofgren is supported by the National Institute of  
334 Mental Health (K23MH121220). Caleb Skipper is supported by the Fogarty International Center  
335 (D43TW009345). Drs. Melanie Nicol, Radha Rajasingham, and Matthew Pullen are supported  
336 by the National Institute of Allergy and Infectious Disease (K08AI134262, K23AI138851,  
337 T32AI055433). Margaret Axelrod is supported by NIH T32GM007347 and F30CA236157. Drs.  
338 Lee and McDonald receive salary support from the Fonds de recherche du Québec – Santé.  
339 Canadian funding was received from various sources. In Quebec, funds were received from the  
340 Clinical Practice Assessment Unit of the McGill University Health Centre and the McGill  
341 Interdisciplinary Initiative in Infection and Immunity's Emergency COVID-19 Research Funding.  
342 In Manitoba, research support was provided from the Manitoba Medical Service Foundation. In  
343 Alberta, support was provided by Northern Alberta Clinical Trials and Research Centre. In  
344 Ontario, support was provided by the Research Institute of St. Joseph's Hamilton, the St  
345 Joseph's Hospital Foundation in London, and Bridge to Health Medical and Dental. Purolator  
346 Canada provided in-kind courier support for Canadian sites participating in the post-exposure  
347 and early treatment trials. Apotex Pharmaceuticals Canada provided a donation of some of the  
348 hydroxychloroquine tablets used. Rising Pharmaceutical donated some of the medicine for U.S.

## *Safety of Hydroxychloroquine in COVID-19*

349 trials. COVID-19 Emergency Supplement funding was requested from the National Institutes of  
350 Health for each of the three trials.

351

352

### 353 **References:**

- 354 1. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS  
355 coronavirus infection and spread. *Virology* **2005**; 2: 69.
- 356 2. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized  
357 Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory  
358 Syndrome Coronavirus 2 (SARS-CoV-2). *Clinical infectious diseases : an official  
359 publication of the Infectious Diseases Society of America* **2020**.
- 360 3. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of  
361 Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *The New England  
362 journal of medicine* **2020**.
- 363 4. Pastick KA, Okafor EC, Wang F, et al. Review: Hydroxychloroquine and Chloroquine for  
364 Treatment of SARS-CoV-2 (COVID-19). *Open Forum Infect Dis* **2020**; 7(4): ofaa130.
- 365 5. RECOVERY Trial. Statement from the Chief Investigators of the Randomised Evaluation  
366 of COVID-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020.  
367 Available at: <https://www.recoverytrial.net/results>. Accessed 5 June 2020.
- 368 6. Cheng MP, Lee TC, Tan DHS, Murthy S. Generating randomized trial evidence to  
369 optimize treatment in the COVID-19 pandemic. *CMAJ : Canadian Medical Association  
370 journal = journal de l'Association medicale canadienne* **2020**; 192(15): E405-E7.
- 371 7. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and  
372 azithromycin in the management of SARS-CoV-2 infection. *CMAJ : Canadian Medical  
373 Association journal = journal de l'Association medicale canadienne* **2020**; 192(17): E450-  
374 E3.
- 375 8. Mercurio NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With  
376 Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among  
377 Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA  
378 Cardiol* **2020**.
- 379 9. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine  
380 Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute  
381 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *JAMA Network Open*  
382 **2020**; 3(4): e208857-e.
- 383 10. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of  
384 the hospital setting or a clinical trial due to risk of heart rhythm problems. Available at:

## Safety of Hydroxychloroquine in COVID-19

- 385 [https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or)  
386 [hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or.](https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or)
- 387 11. Hydroxychloroquine FDA Package Insert. Available at:  
388 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/009768s037s045s047lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf)  
389 [f](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf). Accessed May 1, 2020.
- 390 12. Ross SB, Wilson MG, Papillon-Ferland L, et al. COVID-SAFER: Deprescribing Guidance  
391 for Hydroxychloroquine Drug Interactions in Older Adults. *Journal of the American*  
392 *Geriatrics Society* **2020**.
- 393 13. Guo J, Wei X, Li Q, et al. Single-cell RNA analysis on ACE2 expression provides  
394 insights into SARS-CoV-2 potential entry into the bloodstream and heart injury. *J Cell*  
395 *Physiol* **2020**.
- 396 14. Sharma A, Garcia G, Arumugaswami V, Svendsen CN. Human iPSC-Derived  
397 Cardiomyocytes are Susceptible to SARS-CoV-2 Infection. *bioRxiv* **2020**.
- 398 15. Wu L, O'Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and  
399 cardiovascular complications: From molecular mechanisms to pharmaceutical  
400 management. *Biochem Pharmacol* **2020**; 178: 114114.
- 401 16. Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and  
402 Cardiovascular Disease: COVID-19 Heart. *Heart Lung Circ* **2020**.
- 403 17. Lippi G, South AM, Henry BM. Electrolyte imbalances in patients with severe  
404 coronavirus disease 2019 (COVID-19). *Ann Clin Biochem* **2020**; 57(3): 262-5.
- 405 18. Sacher F, Fauchier L, Boveda S, et al. Use of drugs with potential cardiac effect in the  
406 setting of SARS-CoV-2 infection. *Arch Cardiovasc Dis* **2020**; 113(5): 293-6.
- 407 19. Lothar SA, Abassi M, Agostinis A, et al. Post-exposure prophylaxis or pre-emptive  
408 therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study  
409 protocol for a pragmatic randomized-controlled trial. *Canadian journal of anaesthesia =*  
410 *Journal canadien d'anesthesie* **2020**.
- 411 20. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine  
412 prophylaxis for COVID-19: The desperate search for effectiveness. *Clinical*  
413 *pharmacology and therapeutics* **2020**.
- 414 21. Cheng WF, Kao NC, Tsao KH, Chen CJ, Sun TJ, Wang YC. The Inhibition of  
415 Immunologic Response by Chloroquine. *Chin Med J* **1964**; 83: 531-5.
- 416 22. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A  
417 narrative review for emergency providers. *Am J Emerg Med* **2020**.
- 418 23. Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-  
419 interval prolongation in a patient with systemic lupus erythematosus. *Journal of clinical*  
420 *rheumatology : practical reports on rheumatic & musculoskeletal diseases* **2013**; 19(5):  
421 286-8.

## *Safety of Hydroxychloroquine in COVID-19*

- 422 24. Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin,  
423 cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory  
424 issues: A narrative review based on the study of case reports. *Ther Adv Infect Dis* **2013**;  
425 1(5): 155-65.
- 426 25. The cardiotoxicity of antimalarials. In: *Malaria Policy Advisory Committee Meeting*.  
427 Geneva, Switzerland: World Health Organization (WHO), 2017:1-49.
- 428 26. Glenza J. Brazilian chloroquine study halted after high dose proved lethal for some  
429 patients. Available at: [https://www.theguardian.com/world/2020/apr/24/chloroquine-](https://www.theguardian.com/world/2020/apr/24/chloroquine-study-coronavirus-brazil)  
430 [study-coronavirus-brazil](https://www.theguardian.com/world/2020/apr/24/chloroquine-study-coronavirus-brazil).
- 431 27. Shaw ML. Caution Strongly Recommended When Using Chloroquine,  
432 Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19. Available at:  
433 [https://www.ajmc.com/newsroom/caution-strongly-recommended-when-using-](https://www.ajmc.com/newsroom/caution-strongly-recommended-when-using-chloroquine-hydroxychloroquine-in-patients-with-cardiovascular-disease-covid19)  
434 [chloroquine-hydroxychloroquine-in-patients-with-cardiovascular-disease-covid19](https://www.ajmc.com/newsroom/caution-strongly-recommended-when-using-chloroquine-hydroxychloroquine-in-patients-with-cardiovascular-disease-covid19).
- 435 28. Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity.  
436 *Rheumatology (Oxford)* **2016**; 55(6): 957-67.
- 437 29. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response  
438 relationships in patients with rheumatoid arthritis. *Arthritis Rheum* **2002**; 46(6): 1460-9.
- 439 30. Major US Trial Closes Showing No Benefit for Hydroxychloroquine in COVID-19.
- 440 31. Horby P LM. Correspondence to All RECOVERY Principal Investigators.  
441 [https://www.recoverytrial.net/files/professional-](https://www.recoverytrial.net/files/professional-downloads/recovery_noticetoinvestigators_2020-05-24_1422.pdf)  
442 [downloads/recovery\\_noticetoinvestigators\\_2020-05-24\\_1422.pdf](https://www.recoverytrial.net/files/professional-downloads/recovery_noticetoinvestigators_2020-05-24_1422.pdf): RECOVERY Central  
443 Coordinating Office, **2020**:2.
- 444 32. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions  
445 on QTc Interval in Exploratory COVID-19 Treatment. *Heart Rhythm* **2020**.
- 446 33. Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on Minimizing Risk of Drug-Induced  
447 Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian  
448 Heart Rhythm Society. *The Canadian journal of cardiology* **2020**; 36(6): 948-51.
- 449 34. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. *Heart* **2003**;  
450 89(11): 1363-72.
- 451  
452  
453

*Safety of Hydroxychloroquine in COVID-19*

454 **Table 1. Baseline Demographics for all three cohorts, Post-exposure Prophylaxis,**  
455 **Preemptive Early Treatment, and Pre-exposure prophylaxis**

Demographic	N (%) or Median, [IQR]
Participants	2795
Age in years, median [IQR]	40 [34, 49]
Weight in kg, median [IQR]	79 [66, 91]
Women, N (%)	1423 (51.4%)
Ethnicity (all that apply), N (%)	
White or Caucasian	1972 (71.3%)
Black or African American	72 (2.6%)
Asian or South Asian	527 (19.0%)
Hispanic or Latino	132 (4.8%)
Native American or Pacific Islander	36 (1.3%)
Other or Not Stated	68 (2.5%)
Healthcare worker/First Responder, N (%)	2059 (74.4%)
Current smoker, N (%)	80 (2.9%)
No medications listed, N (%)	1825 (66.0%)
No chronic medical conditions, N (%)	1633 (59.0%)

IQR= Interquartile Range

456  
457  
458

*Safety of Hydroxychloroquine in COVID-19*

**Table 2. Combined Side Effects Days 1-5 in Post-Exposure Prophylaxis and Early Treatment Cohorts**

	Hydroxychloroquine	Placebo	P-value*
Number randomized	658	654	
Started study medication	576 (87.5%)	563 (86.1%)	0.46
Any side effect (days 1-5)**	231 (40.1%)	101 (17.9%)	<b>&lt;0.001</b>
<b>Side Effects**</b>			
Nausea or upset stomach	146 (25.3%)	53 (9.4%)	<b>&lt;0.001</b>
Diarrhea, abdominal pain, vomiting	131 (22.7%)	35 (6.2%)	<b>&lt;0.001</b>
Irritability, dizziness, vertigo	39 (6.8%)	26 (4.6%)	0.13
Tinnitus	16 (2.8%)	8 (1.4%)	0.15
Headache	15 (2.6%)	8 (1.4%)	0.21
Visual changes	7 (1.2%)	5 (0.9%)	0.77
Skin reaction	10 (1.7%)	4 (0.7%)	0.18
Taste change or dry mouth	3 (0.5%)	3 (0.5%)	>0.99
Allergic reaction	6 (1.0%)	1 (0.2%)	0.12
Hot flashes, night sweats or palpitations	2 (0.3%)	1 (0.2%)	>0.99
Fatigue	1 (0.2%)	1 (0.2%)	>0.99
Panic	0 (0.0%)	1 (0.2%)	0.49
Other	1 (0.2%)	2 (0.4%)	0.62

\*P values calculated via Fisher's Exact test. \*\*Of those who started study medication.

*Safety of Hydroxychloroquine in COVID-19*

**Table 3. Odds of Side Effects in Post-exposure Prophylaxis and Early Treatment Cohorts.**

<b>Group</b>	<b>Odds Ratio of Any Side Effect</b>	<b>95% Confidence Interval</b>	<b>P-value*</b>
<b>Women vs. Men</b>	1.163	0.827-1.637	0.39
<b>Healthcare Worker vs. Not</b>	0.796	0.570-1.111	0.18
<b>Age &lt; 35 compared with 35-50 years</b>	1.055	0.707-1.576	0.79
<b>Age &gt; 50 compared with 35-50 years</b>	0.726	0.457-1.151	0.17
<b>Weight &lt; 64kg compared with 64-87 kg</b>	1.421	0.911- 2.218	0.12
<b>Weight &gt; 87kg compared with 64-87 kg</b>	0.744	0.470-1.179	0.21

\*P value calculated via Chi-Square

*Safety of Hydroxychloroquine in COVID-19*

**Table 4. Side Effects from Pre-exposure Prophylaxis Cohort through June 25, 2020**

	Hydroxychloroquine 2x per week	Hydroxychloroquine 1x per week	Placebo	P-value*
Number randomized	495	494	494	
Number with completed Surveys	462	471	469	
Any side effect**	167 (36.2%)	145 (30.8%)	97 (20.7%)	<b>&lt;0.001</b>
Side Effects**				
Nausea or upset stomach	85 (18.4%)	77 (16.3%)	54 (11.5%)	<b>0.04</b>
Diarrhea, abdominal pain, vomiting	75 (16.2%)	56 (11.9%)	30 (6.4%)	<b>&lt;0.001</b>
Arrhythmia, tachycardia, palpitations	8 (1.7%)	8 (1.7%)	11 (2.3%)	0.73
Irritability, dizziness, vertigo	23 (5.0%)	25 (5.3%)	22 (4.7%)	0.92
Tinnitus	6 (1.3%)	10 (2.1%)	4 (0.9%)	0.26
Fatigue	4 (0.9%)	0 (0.0%)	1 (0.2%)	-
Visual changes	4 (0.9%)	7 (1.5%)	3 (0.6%)	0.41
Skin reaction	22 (4.8%)	11 (2.3%)	10 (2.1%)	<b>0.04</b>
Allergic reaction	4 (0.9%)	2 (0.4%)	3 (0.6%)	0.70
Sleep disturbance	6 (1.3%)	8 (1.7%)	4 (0.9%)	0.52
Myalgia	1 (0.2%)	4 (0.8%)	2 (0.4%)	0.38
Arrhythmias	1(0.2%)	0 (0.0%)	1 (0.2%)	-
Other	14 (3.0%)	10 (2.1%)	5 (1.1%)	0.12

\*P values calculated via Fisher's Exact Test comparing hydroxychloroquine (pooled) versus placebo. \*\*Of participants who completed surveys